NEUROTROPHIC FACTOR AND NEUROTRANSMITTER REPLACEMENT

$183,836P01FY2002AGNIH

Salk Institute For Biological Studies, La Jolla CA

Investigators

Linked publications & trials

Paper 29535375 Paper 29045838 Paper 28130011 Paper 28067668 Paper 27558862 Paper 27525439 Paper 27466341 Paper 27419933 Paper 26948893 Paper 26903653 Paper 26620558 Paper 26489892 Paper 26388203 Paper 26341908 Paper 26302439 Paper 26202279 Paper 25803611 Paper 25788688 Paper 25673831 Paper 25533483 Paper 25505106 Paper 25448159 Paper 25173807 Paper 25126588 Paper 25093680 Paper 25024337 Paper 25022790 Paper 24885390 Paper 24825898 Paper 24813892 Paper 24462903 Paper 24068826 Paper 23935974 Paper 23626796 Paper 23413261 Paper 23401561 Paper 23392688 Paper 23384597 Paper 23313024 Paper 23254192 Paper 23223568 Paper 23182244 Paper 23152192 Paper 22989354 Paper 22833673 Paper 22810100 Paper 22647715 Paper 22528101 Paper 22514658 Paper 22508489 Paper 22492998 Paper 22456708 Paper 22314685 Paper 22281106 Paper 22229116 Paper 22211740 Paper 22150925 Paper 22112803 Paper 22066148 Paper 22064070 Paper 21998872 Paper 21994367 Paper 21928509 Paper 21860085 Paper 21403389 Paper 21368891 Paper 21358740 Paper 21304989 Paper 21296890 Paper 21257908 Paper 21103359 Paper 21045796 Paper 20970422 Paper 20679195 Paper 20559548 Paper 20554871 Paper 20445049 Paper 20433905 Paper 20413653 Paper 20181623 Paper 20140000 Paper 20091183 Paper 19944097 Paper 19932737 Paper 19931251 Paper 19864570 Paper 19726646 Paper 19660551 Paper 19651612 Paper 19587288 Paper 19551456 Paper 19535597 Paper 19416837 Paper 19321231 Paper 19198615 Paper 19176820 Paper 19166511 Paper 19135265 Paper 19014502 Paper 19013154

Abstract

In Project 1 we aim to therapeutically deliver trophic factors or neurotransmitter enzymes to protect against age-related dysfunctions found in aged rats or transgenic mouse models of Alzheimer's disease. The degeneration of cholinergic neurons is one of the most consistent findings in AD. We propose to use viral vectors to investigate therapeutic approaches of direct gene delivery to animal models of AD primarily focused on lentiviral vectors. Three complementary strategies will be developed to reverse the morphological and behavior deficits associated with aging in normal aged rats and a transgenic mouse model of AD. The first strategy is to restore function using ChAT to replace or supplement depleted acetylcholine in aged rats. The second strategy places the emphasis on neuroprotection using the NGF gene and product to protect ChAT neurons from age related death, and enhance the function of the remaining neurons. A progression within these two strategies from constitutive to regulatable expression will be made as we improve our lentiviral vectors. The third strategy focuses on the interplay between amyloid precursor protein (APP), and the cholinergic system. Lentiviral factors delivering either NGF or ChAT will be injected into the hippocampus of transgenic animals over expressing APP to elucidate whether the cholinergic system regulates amyloid processing, alters plaque formation, or may improve behavioral performance. Functional and anatomical effects of direct gene delivery of choline acetyltransferase (ChAT) and nerve growth factor (NGF) to the aged brain have not been evaluated. Using lentiviral vectors, we can deliver these molecules to discrete populations of cells within the central nervous system (CNS), measuring the effects of direct (ChAT), or indirect (NGF) cholinergic enhancement on cognition, neuronal and synaptic changes, and amyloid processing.

View original record on NIH RePORTER →